一种新的青光眼治疗途径:小梁网干细胞再生
青光眼是全球不可逆性盲的首位病因,需要比现有疗法更有效的新治疗选择。小梁网细胞对房水流出通路的维持和功能有重要作用,研究发现在青光眼中小梁网细胞数量减少。过去几十年有多篇报告提出用干细胞再生小梁网作为新的治疗选择。多种干细胞已在青光眼动物模型和离体模型中使用,在眼压稳态和小梁网细胞数量恢复方面显示成功,并在相当长的时间内表现出稳定性且无严重副作用。基于目前对小梁网病理的认识和干细胞再生该组织的现有文献,作者提出下一步应开展人体临床研究。
要点
- 青光眼中小梁网细胞数量减少,干细胞再生小梁网被提出为新的治疗选择。
- 多种干细胞在青光眼动物模型和离体模型中显示可恢复眼压稳态和小梁网细胞数量。
- 干细胞在相当长时间内表现出稳定性且无严重副作用。
核心结论
- 基于目前对小梁网病理的认识和干细胞再生该组织的现有文献,作者提出下一步应开展人体临床研究,以理解这一潜在革命性治疗范式。
- 保护和替换青光眼眼中小梁网细胞的能力可能永远改变该领域。
研究设计与样本
- 综述类:文章汇总了干细胞再生小梁网作为青光眼新治疗选择的现有文献,并提出人体临床研究作为下一步。
主要发现
- 青光眼是全球不可逆性盲的首位病因,需要比现有疗法更有效的新治疗选择。
- 小梁网细胞对房水流出通路的维持和功能有重要作用,研究发现在青光眼中存在小梁网细胞数量减少。
- 过去几十年有多篇报告提出用干细胞再生小梁网作为新的治疗选择。
- 已在眼部再生医学中研究多种干细胞:组织特异性干细胞、胚胎干细胞、诱导多能干细胞和成体间充质干细胞。
- 这些细胞已在多种青光眼动物模型和离体模型中使用,在眼压稳态和小梁网细胞数量恢复方面显示成功,并在相当长的时间内表现出稳定性且无严重副作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glaucoma is the leading cause of global irreversible blindness, necessitating research for new, more efficacious treatment options than currently exist. Trabecular meshwork (TM) cells play an important role in the maintenance and function of the aqueous outflow pathway, and studies have found that there is decreased cellularity of the TM in glaucoma. Regeneration of the TM with stem cells has been proposed as a novel therapeutic option by several reports over the last few decades. Stem cells have the capacity for self-renewal and the potential to differentiate into adult functional cells. Several types of stem cells have been investigated in ocular regenerative medicine: tissue specific stem cells, embryonic stem cells, induced pluripotent stem cells, and adult mesenchymal stem cells. These cells have been used in various glaucoma animal models and ex vivo models and have shown success in IOP homeostasis and TM cellularity restoration. They have also demonstrated stability without serious side effects for a significant period of time. Based on current knowledge of TM pathology in glaucoma and existing literature regarding stem cell regeneration of this tissue, we propose a human clinical study as the next step in understanding this potentially revolutionary treatment paradigm. The ability to protect and replace TM cells in glaucomatous eyes could change the field forever.
引用
- Coulon SJ, Schuman JS, Du Y, et al. A novel glaucoma approach: Stem cell regeneration of the trabecular meshwork. Prog Retin Eye Res. 2022. PMID: 35398015. doi:10.1016/j.preteyeres.2022.101063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。